EUVIMEDEUVIMED entdecken
Systematische Übersicht

A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development

Kristine Broglio, Freda Cooner, Yujun Wu, Mike Xiao, X Q Xue, Marina Lowen, Izuagie Ikhapoh, Philip He

Therapeutic Innovation & Regulatory Science · 2024

DOI: 10.1007/s43441-024-00670-1 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2024. Verfasst von Kristine Broglio und 7 weiteren Autor:innen. Beteiligte Einrichtung: AstraZeneca, Gaithersburg, MD, USA. kristine.broglio@astrazeneca.com. Hauptthemen laut MEDLINE: Neoplasms, Research Design. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Although oncology has seen large scientific and clinical advances over the last decade, it also has one of the lowest success rates for novel agents across therapeutic areas. Adaptive clinical trial design has been a popular option for increasing clinical trial efficiency and the chances of trial success. Seamless clinical trial design are studies in which two or more clinical trial phases are combined into a single study with a pre-specified transition between stages. This integration of phases may enhance efficiency. METHODS: To understand the precedent for the use of seamless designs, this working group was formed to conduct a comprehensive literature search on seamless clinical trials conducted with confirmatory intent in oncology. Trial design features were extracted into a database and analyzed with descriptive statistics. RESULTS: A literature search identified 68 clinical trials meeting inclusion and exclusion criteria. The most common design feature was a gate on treatment efficacy, where the trial would only proceed to the second stage if sufficient efficacy was observed in the first. The next most common feature was a selection of a dose or treatment regimen. Inferentially and operationally seamless designs were approximately equally represented. DISCUSSION: Key statistical considerations for seamless phase II/III designs include optimizing design choices by evaluating and comparing operating characteristics across design alternatives as well as showing control of overall Type I error rates. Executing the transition between phases should be evaluated for issues related to accrual, drug production, and procedures to maintain trial integrity. CONCLUSIONS: While there are unique statistical, regulatory, and operational considerations for seamless designs they are also uniquely suited to many development settings. These include, for example, addressing dose selection under FDA's Project Optimus and addressing the growing use of biomarkers and personalized medicine approaches in cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsResearch DesignHumansMedical OncologyAdaptive Clinical Trials as TopicDrug DevelopmentAntineoplastic AgentsClinical Trials as Topic

Stichwörter der Autor:innen

Adaptive designConfirmatory trialsDose optimizationEnrichmentSeamless

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • AstraZeneca, Gaithersburg, MD, USA. kristine.broglio@astrazeneca.com.
  • Eli Lilly and Company, Indianapolis, IN, USA.
  • Morphic Therapeutic, Waltham, MA, USA.
  • Daiichi Sankyo Inc, Basking Ridge, NJ, USA.
  • Syneos Health, Morrisville, NC, USA.
  • AstraZeneca, Gaithersburg, MD, USA.

Zitieren

APA

Broglio, K., Cooner, F., Wu, Y., Xiao, M., Xue, X. Q., Lowen, M., Ikhapoh, I., & He, P. (2024). A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00670-1

Vancouver

Broglio K, Cooner F, Wu Y, Xiao M, Xue XQ, Lowen M, et al. A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development. Therapeutic Innovation & Regulatory Science. 2024. doi:10.1007/s43441-024-00670-1

BibTeX
@article{Broglio2024,
  author = {Broglio, Kristine and Cooner, Freda and Wu, Yujun and Xiao, Mike and Xue, X Q and Lowen, Marina and Ikhapoh, Izuagie and He, Philip},
  title = {A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2024},
  doi = {10.1007/s43441-024-00670-1}
}
Kostenlos starten →